Beck Bode’s iShares Biotechnology ETF IBB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-1,350
Closed -$257K – 109
2026
Q2
$257K Buy
1,350
+46
+4% +$7.91K 0.04% 92
2026
Q1
$220K Sell
1,304
-464
-26% -$79.3K 0.04% 87
2025
Q4
$298K Sell
1,768
-237
-12% -$38.5K 0.05% 83
2025
Q3
$289K Sell
2,005
-398
-17% -$54.3K 0.05% 83
2025
Q2
$304K Sell
2,403
-1,216
-34% -$149K 0.05% 88
2025
Q1
$463K Sell
3,619
-787
-18% -$107K 0.09% 80
2024
Q4
$583K Sell
4,406
-1,900
-30% -$267K 0.11% 87
2024
Q3
$918K Sell
6,306
-2,640
-30% -$382K 0.17% 74
2024
Q2
$1.23M Sell
8,946
-2,506
-22% -$335K 0.25% 67
2024
Q1
$1.57M Sell
11,452
-1,728
-13% -$236K 0.32% 71
2023
Q4
$1.79M Sell
13,180
-230
-2% -$28.1K 0.4% 70
2023
Q3
$1.64M Sell
13,410
-552
-4% -$70.2K 0.42% 69
2023
Q2
$1.77M Sell
13,962
-703
-5% -$91.3K 0.43% 67
2023
Q1
$1.89M Sell
14,665
-1,290
-8% -$169K 0.47% 66
2022
Q4
$2.09M Sell
15,955
-190
-1% -$24.6K 0.47% 63
2022
Q3
$1.89M Buy
+16,145
New +$2M 0.41% 68

Other funds holding IBB

Beck Bode's IBB Position: Q3 2026 in Review

Beck Bode sold out of iShares Biotechnology ETF (IBB) in Q3 2026, closing a stake of 1,350 shares — an estimated $257K sold.

Beck Bode first reported a position in IBB in Q3 2022 and held it in 16 quarters. The position peaked at $2.09M in Q4 2022. 907 funds tracked by Wall St. Rank hold IBB as of Q3 2026.

  • Beck Bode reported no remaining iShares Biotechnology ETF position as of Q3 2026 after selling out during the quarter.
  • Beck Bode sold 1,350 iShares Biotechnology ETF shares in Q3 2026, an estimated $257K.
  • Beck Bode first reported a position in iShares Biotechnology ETF in Q3 2022 and held it in 16 quarters.
  • Beck Bode's iShares Biotechnology ETF position peaked at $2.09M in Q4 2022.
  • 907 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q3 2026.

Based on Beck Bode's 13F filing for Q3 2026, filed 12 Nov 2026.